Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model

Transplantation

Volumn 64, Issue 9, 1997, Pages 1343-1352

  Yang, Yong Guang ^a   Dey, Bimalangshu ^a   Sergio, Justin J ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; DIARRHEA; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNE FUNCTION TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CATTLE; CHRONIC DISEASE; CRICETINAE; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED STRAINS; RATS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TISSUE DONORS;

EID: 0030724881     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711150-00018     Document Type: Article

References (48)

1. Mortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. III. Results of the 1988-1990 survey. Ann Intern Med 1992; 116: 505.
2. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677.
3. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249.
4. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501.
5. Beatty PG, Clift RA, Mickelson FM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
6. Bortin MM. Bone marrow transplantation for leukemia using family donors other than HLA-identical siblings: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc 1987; 19: 2629.
7. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 88: 193.
8. Ringden O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39.
9. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199.
10. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827.
11. Chouaib S, Chehimi J, Bani L, et al. Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91: 12659.
12. Sykes M, Szot GL, Nguyen PL, Pearson DA. Interleukin-12 inhibits murine graft-vs-host disease. Blood 1995; 86: 2429.
13. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant 1990; 5: 209.
14. Moser M, Iwasaki T, Shearer GM. Cellular interactions in graft-versus-host -induced T cell immune deficiency. Immunol Rev 1985; 88: 135.
15. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA. The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol Rev 1985; 88: 107.
16. Dialynas DP, Quan ZS, Wall KA, et al. Characterization of murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to human Leu3/T4 molecule. J Immunol 1983; 131: 2445.
17. Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 1980; 125: 2665.
18. Sykes M, Abraham VS, Harty MW, Pearson DA. IL-2 reduces graft-vs-host disease and preserves a graft-vs-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol 1993; 150: 197.
19. Sykes M, Sharabi Y, Sachs DH. Natural suppressor cells in spleens of irradiated, bone marrow reconstituted mice and normal bone marrow: lack of Sca-1 expression and enrichment by depletion of Mac1-positive cells. Cell Immuol 1990; 127: 260.
20. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990; 171: 645.
21. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979; 150: 580.
22. Bradley LM, Atkins GG, Swain SL. Long-term CD4+ memory T cells from the spleen lack Mel-14, the lymph node homing receptor. J Immunol 1992; 148: 324.
23. Swain SL, Croft M, Dubey C, et al. From naive to memory T cells. Immunol Rev 1996; 150: 143.
24. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994; 179: 1127.
25. Tough DF, Sprent J. Thymic emigration: a reply. Immunol Today 1995; 16: 273.
26. Acha-Orbea H, Held W, Waanders GA, et al. Exogenous and endogenous mouse mammary tumor virus superantigens. Immunol Rev 1993; 131: 5.
27. Simpson E, Dyson PJ, Knight AM, Robinson PJ, Elliott JI, Altmann DM. T-cell receptor repertoire selection by mouse mammary tumor viruses and MHC molecules. Immunol Rev 1993; 131: 93.
28. Tomonari K, Fairchild S, Rosenwasser OA. Influence of viral superantigens on Vb- and Va-specific positive and negative selection. Immunol Rev 1993; 131: 131.
29. Yang Y-G, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-vs-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-vs-host disease in mice. Blood (in press).
30. Singer A, Hathcock KS, Hodes RJ. Self recognition in allogeneic radiation chimeras: a radiation resistant host element dictates the self specificity and immune response gene phenotype of T-helper cells. J Exp Med 1981; 153: 1286.
31. Gleichmann H, Gleichmann E, Andre-Schwartz J, Schwartz RS. Chronic allogeneic disease. III. Genetic requirements for the induction of glomerulonephritis. J Exp Med 1972; 135: 516.
32. Reap EA, Sovel ES, Jennette JC, Cohen PL, Eisenberg RA. Conventional B cells, not B1 cells, are the source of autoantibodies in chronic graft-versus-host disease. J Immunol 1993; 151: 7316.
33. Via CS, Shearer GM. Murine graft-versus-host disease as a model for the development of autoimmunity: relevance of cytotoxic T lymphocytes. Ann NY Acad Sci 1988; 532: 44.
34. Morris SC, Cheek RL, Cohen PL, Eisenberg RA. Autoantibodies in chronic graft versus host result from cognate T-B interactions. J Exp Med 1990; 171: 503.
35. Desbarats J, Lapp WS. Thymic selection and thymic major histocompatibility complex class II expression are abnormal in mice undergoing graft-versus-host reactions. J Exp Med 1993; 178: 805.
36. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol 1994; 152: 1609.
37. + T helper cell function. J Immunol 1987; 138: 1355.
38. Via CS, Sharrow SO, Shearer GM. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol 1987; 139: 1840.
39. Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of graft-vs.-host induced severely dysplastic thymuses. Am J Pathol 1988; 133: 25.
40. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391.
41. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307(5947): 168.
42. Marrack P, Lo D, Brinster R, et al. The effect of thymus environment on T cell development and tolerance. Cell 1988; 53: 627.
43. Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445.
44. Poynton CH. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988; 3: 265.
45. Butturini A, Gale RP. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 265.
46. Verdonck LF, van Blokland WTM, Bosboom-Kalsbeek EK, Van Heugten HG, Tilanus MGJ, de Weger RA. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells. Bone Marrow Transplant 1996; 18: 389.
47. Kaufman CL, Chambers WH, Ildstad ST. Coexpression of NKR-P1 and ab-TCR on lymphoid cells in fully xenogeneic (rat→mouse) chimeras and syngeneically reconstituted (AAA) rats. J Immunol 1993; 151: 6002.
48. Hashimoto W, Takeda K, Anzai R, et al. Cytotoxic NK1.1 Ag+ ab T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995; 154: 4333.